Open AccessTHYROID DYSFUNCTION
Author(s) -
Maham Mehmood,
Muhammad Arshad Qureshi,
Ijaz Ul Haque Taseer
Publication year - 2015
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2015.22.02.1373
Subject(s) - medicine , ribavirin , levothyroxine , gastroenterology , pegylated interferon , chronic hepatitis , population , hepatitis c , prospective cohort study , thyroid dysfunction , thyroid disease , thyroid , immunology , virus , environmental health
Hepatitis C is a burning issue. Prevalence of hepatitis C virus reported in Pakistanis 5% with areas of high infection in different cities and subsets of population. Objectives: Tofind out the frequency of thyroid related dysfunctions in chronic hepatitis C patients on Peg-Interferon Alpha-2a and Ribavirin therapy. Study Design: A prospective cohort study. Placeand Duration of Study: Hepatitis Center DHQ teaching hospital Sahiwal from July 2013 to June2014. Material and Methods: We studied 100 patients of chronic HCV infection with baselinelevel of TSH,T3 and T4. Baseline serum ALT and serum AST were also measured. Patients wereput on Peg-Interferon Alpha-2a (180 ug) weekly and Ribavirin (800 to 1000 mg/d) for 24weeks.All patients were followed up for thyroid dysfunction at weeks 0, 12, 18 and 24. Result: Outof 100 treated patients 65 were female and 35 were male. Fifteen (15%) patients developedthyroid dysfunction and out of these 15 patients (11 female [73.3%] and 4 male [26.7%]).Ten (66.6%) out of 15 patients developed hypothyroidism and 5(33.3%) out of 15 patientsdeveloped hyperthyroidism. Seven (70%) out of 10 patients who developed hypothyroidismneeded levothyroxine therapy. Two (40%) out of 5 patients who developed hyperthyroidismneeded carbimazol therapy for their symptoms and disease control. All patients completedhepatitis C treatment with combined Peg-Interferon Alpha-2a and Ribavirin therapy.